S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)

AbCellera Biologics (ABCL) Stock Forecast, Price & News

$4.60
-0.06 (-1.29%)
(As of 09/29/2023 ET)
Compare
Today's Range
$4.57
$4.75
50-Day Range
$4.66
$7.85
52-Week Range
$4.51
$14.97
Volume
1.51 million shs
Average Volume
2.18 million shs
Market Capitalization
$1.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.13

AbCellera Biologics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
402.7% Upside
$23.13 Price Target
Short Interest
Bearish
12.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.61mentions of AbCellera Biologics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.51) to ($0.63) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

778th out of 973 stocks

Pharmaceutical Preparations Industry

370th out of 450 stocks


ABCL stock logo

About AbCellera Biologics (NASDAQ:ABCL) Stock

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

ABCL Price History

ABCL Stock News Headlines

Argenx's 28% Surge & Promising Product Propel Investor Confidence (ABCL)
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
AbCellera's Clinical Carousel: High Risk, Higher Stakes
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
10 Stocks That Could 10X Over the Next 10 Years
Q2 2023 Abcellera Biologics Inc Earnings Call
AbCellera Reports Q2 2023 Business Results
Earnings Preview: AbCellera Biologics
See More Headlines
Receive ABCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter.

ABCL Company Calendar

Last Earnings
8/03/2023
Today
9/29/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABCL
Fax
N/A
Employees
590
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$23.13
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+397.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$158.52 million
Pretax Margin
-48.89%

Debt

Sales & Book Value

Annual Sales
$485.42 million
Cash Flow
$0.66 per share
Book Value
$4.31 per share

Miscellaneous

Free Float
195,460,000
Market Cap
$1.35 billion
Optionable
Not Optionable
Beta
0.01
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Carl L.G. Hansen Ph.D. (Age 48)
    CEO, Pres & Chairperson
    Comp: $711.47k
  • Mr. Andrew Booth M.B.A.Mr. Andrew Booth M.B.A. (Age 49)
    Chief Financial Officer
    Comp: $642.42k
  • Dr. Veronique Lecault Ph.D. (Age 38)
    COO & Director
    Comp: $645.07k
  • Mr. Tryn T. Stimart Esq. (Age 53)
    J.D., Chief Legal Officer, Chief Compliance Officer & Corp. Sec.
    Comp: $644.4k
  • Mr. Neil Aubuchon M.B.A. (Age 53)
    Chief Commercial Officer
    Comp: $684.81k
  • Marcie Thiessen CPA
    CGA, Sr. Director of Fin. & Accounting
  • Dr. Ester Falconer Ph.D. (Age 48)
    Chief Technology Officer
  • Josephine Hellschlienger Ph.D.
    Mang. of Investor Relations
  • Ms. Tiffany Chiu B.Sc.
    Ph.D., VP of Communications
  • Alexandra Weirich M.Sc.
    Mang. of Marketing & Communications













ABCL Stock - Frequently Asked Questions

Should I buy or sell AbCellera Biologics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ABCL shares.
View ABCL analyst ratings
or view top-rated stocks.

What is AbCellera Biologics' stock price forecast for 2023?

8 brokerages have issued 1 year price objectives for AbCellera Biologics' stock. Their ABCL share price forecasts range from $12.00 to $34.00. On average, they expect the company's share price to reach $23.13 in the next twelve months. This suggests a possible upside of 397.3% from the stock's current price.
View analysts price targets for ABCL
or view top-rated stocks among Wall Street analysts.

How have ABCL shares performed in 2023?

AbCellera Biologics' stock was trading at $10.13 on January 1st, 2023. Since then, ABCL stock has decreased by 54.1% and is now trading at $4.65.
View the best growth stocks for 2023 here
.

When is AbCellera Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ABCL earnings forecast
.

How were AbCellera Biologics' earnings last quarter?

AbCellera Biologics Inc. (NASDAQ:ABCL) released its earnings results on Thursday, August, 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. The firm earned $10.10 million during the quarter, compared to analyst estimates of $12.38 million. AbCellera Biologics had a negative trailing twelve-month return on equity of 6.05% and a negative net margin of 50.91%. The firm's revenue for the quarter was down 78.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.02) earnings per share.

What ETFs hold AbCellera Biologics' stock?

ETFs with the largest weight of AbCellera Biologics (NASDAQ:ABCL) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM).TrueShares Technology, AI & Deep Learning ETF (LRNZ).

When did AbCellera Biologics IPO?

(ABCL) raised $356 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 23,000,000 shares at $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets served as the underwriters for the IPO.

What is AbCellera Biologics' stock symbol?

AbCellera Biologics trades on the NASDAQ under the ticker symbol "ABCL."

How do I buy shares of AbCellera Biologics?

Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AbCellera Biologics' stock price today?

One share of ABCL stock can currently be purchased for approximately $4.65.

How much money does AbCellera Biologics make?

AbCellera Biologics (NASDAQ:ABCL) has a market capitalization of $1.35 billion and generates $485.42 million in revenue each year. The company earns $158.52 million in net income (profit) each year or ($0.27) on an earnings per share basis.

How many employees does AbCellera Biologics have?

The company employs 590 workers across the globe.

How can I contact AbCellera Biologics?

The official website for the company is www.abcellera.com. The company can be reached via phone at 604-559-9005 or via email at ir@abcellera.com.

This page (NASDAQ:ABCL) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -